Cardiovascular and kidney outcomes with canagliflozin according to type 2 diabetes treatment targets at baseline: Data from the CANVAS programme and CREDENCE

Michael A Tsoukas¹, Vincent Woo², Sheldon W Tobe^{3

4}, April Slee⁵, Wally Rapattoni⁶, Fernando G Ang⁶, Jochen Seufert⁷, Brendon L Neuen⁸, Clare Arnott^{8

9

10

11}, Kenneth W Mahaffey¹², David C Wheeler¹³

Affiliations

¹ McGill University Health Centre, Montreal, Québec, Canada.
² University of Manitoba, Winnipeg, Manitoba, Canada.
³ Sunnybrook Research Institute, Toronto, Ontario, Canada.
⁴ Northern Ontario School of Medicine, Sudbury, Ontario, Canada.
⁵ New Arch Consulting, Seattle, Washington, USA.
⁶ Janssen, Inc., Toronto, Ontario, Canada.
⁷ Division of Endocrinology and Diabetology, Department of Medicine II, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
⁸ The George Institute for Global Health, UNSW Sydney, Sydney, New South Wales, Australia.
⁹ Faculty of Medicine, UNSW Sydney, Sydney, New South Wales, Australia.
¹⁰ Department of Cardiology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.
¹¹ Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia.
¹² Stanford Center for Clinical Research, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA.
¹³ Centre for Nephrology, University College London, London, UK.

Michael A Tsoukas et al. Diabetes Obes Metab. 2023 Jul.

. 2023 Jul;25(7):2038-2042.

doi: 10.1111/dom.15057. Epub 2023 Apr 4.

¹ McGill University Health Centre, Montreal, Québec, Canada.
² University of Manitoba, Winnipeg, Manitoba, Canada.
³ Sunnybrook Research Institute, Toronto, Ontario, Canada.
⁴ Northern Ontario School of Medicine, Sudbury, Ontario, Canada.
⁵ New Arch Consulting, Seattle, Washington, USA.
⁶ Janssen, Inc., Toronto, Ontario, Canada.
⁷ Division of Endocrinology and Diabetology, Department of Medicine II, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
⁸ The George Institute for Global Health, UNSW Sydney, Sydney, New South Wales, Australia.
⁹ Faculty of Medicine, UNSW Sydney, Sydney, New South Wales, Australia.
¹⁰ Department of Cardiology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.
¹¹ Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia.
¹² Stanford Center for Clinical Research, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA.
¹³ Centre for Nephrology, University College London, London, UK.

No abstract available

Keywords: canagliflozin; cardiovascular disease; diabetic nephropathy; type 2 diabetes.

References

1. Davies MJ, Aroda VR, Collins BS, et al. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of diabetes (EASD). Diabetes Care. 2022;2022(45):2753-2786.
1. Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int. 2022;102(5S):S1-S127.
1. American Diabetes Association. Introduction: standards of medical care in diabetes-2023. Diabetes Care. 2023;46:S1-S291.
1. Diabetes Canada Clinical Practice Guidelines Expert Committee. 2018 clinical practice guidelines. Can J Diabetes. 2018;42:S1-S325.
1. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644-657.